Abbott Laboratories
ABT124.670USD
+0.240+0.19%
Handelsschluss 10/30, 16:00（ET）Kurse um 15 Minuten verzögert
216.79BMarktkapitalisierung
15.51KGV TTM
mehr Informationen über Abbott Laboratories Unternehmen
Abbott Laboratories ist ein US‑amerikanisches multinationales Unternehmen im Gesundheits‑ und Medizintechnik‑Sektor mit Hauptsitz in Abbott Park (Illinois). Gegründet 1888 von Dr. Wallace Calvin Abbott in Chicago, spezialisierte sich das Unternehmen zunächst darauf, wirksame Arznei‑Bestandteile in präzisen Dosierungen bereitzustellen. Heute produziert Abbott medizinische Geräte, Diagnostika, Marken‑Generika sowie Spezialnahrung für unterschiedliche Ernährungsbedürfnisse. 2013 gliederte Abbott seine forschungsorientierte Pharmasparte aus; sie firmiert seitdem als AbbVie.
Zu den bekannten Abbott‑Marken zählen Pedialyte (orale Rehydratationslösung), Similac (Säuglingsnahrung), BinaxNOW (COVID‑19‑Antigen‑Schnelltest), Ensure (hochkalorische Trinknahrung), Glucerna (Diätnahrung für Diabetiker), ZonePerfect (Protein‑ & Energieriegel), FreeStyle Libre (kontinuierliches Glukosemesssystem), i‑STAT (tragbares Blutanalysegerät) und MitraClip (minimal‑invasives Mitralklappen‑Implantat).
Abbott Laboratories Informationen
BörsenkürzelABT
Name des UnternehmensAbbott Laboratories
IPO-datumMar 01, 1937
CEOMr. Robert B. Ford
Anzahl der mitarbeiter114000
WertpapierartOrdinary Share
GeschäftsjahresendeMar 01
Addresse100 Abbott Park Road
StadtABBOTT PARK
BörseNYSE Consolidated
LandUnited States of America
Postleitzahl60064-3500
Telefon12246676100
Websitehttps://www.abbott.com
BörsenkürzelABT
IPO-datumMar 01, 1937
CEOMr. Robert B. Ford
Führungskräfte von Abbott Laboratories
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-0.75%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-2.76%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Andere
4.53B
40.67%
Nach RegionUSD
Name
Umsatz
Anteil
All other Countries
6.87B
61.62%
United States
4.28B
38.38%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Diabetes Care
1.98B
17.78%
Core Laboratory
1.36B
12.19%
Adult Nutritionals
1.16B
10.39%
Key Emerging Markets
1.06B
9.50%
Pediatric Nutritionals
1.05B
9.46%
Andere
4.53B
40.67%
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.89%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Investment Management (US)
4.51%
Capital International Investors
3.46%
Capital Research Global Investors
2.40%
Andere
74.65%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.89%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Investment Management (US)
4.51%
Capital International Investors
3.46%
Capital Research Global Investors
2.40%
Andere
74.65%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
46.33%
Investment Advisor/Hedge Fund
22.98%
Research Firm
3.62%
Bank and Trust
2.25%
Pension Fund
2.21%
Sovereign Wealth Fund
1.37%
Insurance Company
1.06%
Individual Investor
0.48%
Hedge Fund
0.44%
Andere
19.25%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
4555
1.40B
80.58%
-14.37M
2025Q2
4616
1.41B
81.28%
+6.94M
2025Q1
4644
1.42B
81.42%
+12.91M
2024Q4
4535
1.39B
80.22%
+15.89M
2024Q3
4391
1.36B
78.29%
-11.85M
2024Q2
4400
1.36B
78.24%
-7.03M
2024Q1
4402
1.35B
77.67%
-9.71M
2023Q4
4429
1.35B
77.56%
-11.05M
2023Q3
4298
1.34B
77.39%
-25.33M
2023Q2
4297
1.35B
77.60%
-13.55M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
172.03M
9.88%
+2.96M
+1.75%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
88.52M
5.09%
+696.11K
+0.79%
Jun 30, 2025
State Street Investment Management (US)
78.35M
4.5%
+689.52K
+0.89%
Jun 30, 2025
Capital International Investors
60.14M
3.46%
-6.69M
-10.01%
Jun 30, 2025
Capital Research Global Investors
41.77M
2.4%
-8.97M
-17.68%
Jun 30, 2025
Geode Capital Management, L.L.C.
38.29M
2.2%
+1.39M
+3.77%
Jun 30, 2025
JP Morgan Asset Management
26.38M
1.52%
-2.42M
-8.39%
Jun 30, 2025
Wellington Management Company, LLP
25.05M
1.44%
-4.71M
-15.83%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
22.25M
1.28%
+1.27M
+6.03%
Jun 30, 2025
Wells Fargo Advisors
15.18M
0.87%
-240.50K
-1.56%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Oct 2
Aktualisiert: Thu, Oct 2
Name
Anteil
iShares U.S. Medical Devices ETF
18.52%
Goldman Sachs Future Health Care Equity ETF
6.46%
SMI 3Fourteen Full-Cycle Trend ETF
5.18%
Tema Heart & Health ETF
4.68%
Health Care Select Sector SPDR Fund
4.64%
Proshares Ultra Health Care
4.64%
iShares U.S. Healthcare ETF
4.44%
AdvisorShares Focused Equity ETF
4.42%
Invesco Pharmaceuticals ETF
4.35%
Polen Capital Global Growth ETF
4.27%
Mehr Anzeigen
iShares U.S. Medical Devices ETF
Anteil18.52%
Goldman Sachs Future Health Care Equity ETF
Anteil6.46%
SMI 3Fourteen Full-Cycle Trend ETF
Anteil5.18%
Tema Heart & Health ETF
Anteil4.68%
Health Care Select Sector SPDR Fund
Anteil4.64%
Proshares Ultra Health Care
Anteil4.64%
iShares U.S. Healthcare ETF
Anteil4.44%
AdvisorShares Focused Equity ETF
Anteil4.42%
Invesco Pharmaceuticals ETF
Anteil4.35%
Polen Capital Global Growth ETF
Anteil4.27%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
16.46B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Dec 13, 2024
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 09, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 17, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Dec 09, 2022
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 15, 2022
ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
